Fig. 2: Genomic landscape of the NIBIT-M4 trial. | Nature Communications

Fig. 2: Genomic landscape of the NIBIT-M4 trial.

From: Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial

Fig. 2

Oncoplot of frequent somatic nonsynonymous and copy number alterations of NIBIT-M4 trial organized by response (columns, non-responder (NR, n = 8) and responder (R, n = 6) patients) and pathways (rows). Tumor Mutation Burden (TMB), dose (30, 45, and 60 mg/m2/day), and time (week 0, week 4, week 12) of treatments are indicated. The proportion of alterations in NR and R groups is visualized for each gene (p value of two-sided Pearson’s chi-squared test statistic, *p < 0.05, **p < 0.01, ***p < 0.001). Source data are available in Supplementary Data 1.

Back to article page